FDA refuses a filing application for Xaracoll (bupivacaine-collagen matrix) in pain treatment- Innocoll
Innocoll has received a Refusal to File letter from the United States Food and Drug Administration (FDA) for Xaracoll (bupivacaine-collagen matrix), for the treatment of postsurgical pain. Upon preliminary review, the FDA determined that the application, which was submitted in October 2016, was not sufficiently complete to permit a substantive review.
In the Refusal to File letter, the FDA indicated among other things, that Xaracoll should be characterized as a drug/device combination, which would require that the Company submit additional information. The company will request a Type A meeting with the FDA to respond to several issues believed to be addressable and seek clarification of what additional information, if any, will be required. Additional details will be disclosed in the future after discussions with the FDA.
Comment: the therapy is a surgically implantable and bioresorbable bupivacaine-collagen matrix that utilizes our CollaRx proprietary collagen-based delivery technology and is being developed to provide sustained postsurgical pain relief directly into the surgical site.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins